This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

"Stress and the aging brain: the interplay between genetic susceptibility, aging and psychosocial stress on early symptoms of dementia"

STAGED

As the population is growing older, the risk for dementia increases. The complexity of dementia calls for a multidisciplinary approach; in this project I will combine the research fields of Epidemiology, Genetics, Psychology and Cognitive Neuroscience. It is crucial to identify persons at risk for developing dementia, as possible treatment...

Funding Programme
Start Date
End Date
Total Funding
€ 136 064
European Countries Involved

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease

NILVAD

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even...

Funding Programme
Start Date
End Date
Total Funding
€ 7 916 016

A systems pharmacology approach to the discovery of novel therapeutics in Alzheimer´s disease

SYSPHARMAD

Alzheimer´s disease (AD) is the most common form of dementia, with over 35 million people suffering from it worldwide, and it constitutes a personal and societal tragedy of immense proportions. Fifty years of intense research have revealed many key elements of the biology of this neurodegenerative disorder. However, our understanding of the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 296 000
European Countries Involved

A Treatment-Oriented Research Project of NCL Disorders as a Major Cause of Dementia in Childhood

DEM-CHILD

The DEM-CHILD project focusses on the main cause for childhood dementia in Europe, the neuronal ceroid lipofuscinoses (NCLs). The NCLs are neurodegenerative diseases characterized by dementia, blindness, epilepsy and physical decline leading to an early death of the patients. Since no cure is currently available, these disorders represent a serious...

Funding Programme
Start Date
End Date
Total Funding
€ 3 971 420
European Countries Involved

A WORLDWIDE E-INFRASTRUCTURE FOR COMPUTATIONAL NEUROSCIENTISTS (outGRID)

outGRID

FP7 neuGRID (www.neuGRID.eu) is being developed aiming to provide large sets of brain images paired with grid-based computationally intensive algorithms for studies of neurodegenerative diseases. Two infrastructures with similar aims are operational or under construction overseas. In Canada, the Montreal Neurological Institute (MNI) aims to develop...

Funding Programme
Start Date
End Date
Total Funding
€ 491 677
European Countries Involved

Age-modified forms of Amyloid-β as initiator of Alzheimer Disease pathogenesis and mediator of Aβ-tau interaction: a study in a Drosophila model and Aβ immunized human Alzheimer patients

ALZPROTAGEING

Alzheimer Disease (AD) is the commonest form of dementia, with ageing as the main risk factor. There are currently over 6 million people with dementia in the European Union (EU). The increasingly ageing population makes AD an economic and social burden for our society, thus investigating the pathological mechanisms of AD and the characterization of...
Funding Programme
Start Date
End Date
Total Funding
€ 221 606
European Countries Involved

Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer’s disease: Relating the Impact of Amyloid Burden with PIB-PET on Neuronal Activation as Assessed with fMRI

MCI_AD PIB-PET_FMRI

The main objective of this first 2-year period as a post-doctoral research fellow at BWH/MGH Harvard Medical School is to get training in novel Magnetic Resonance Imaging (MRI) and Pittsburgh Compound B–Positron Emission Tomography (PIB-PET) techniques, their analysis methods, and applications to aging and age-related neurodegenerative diseases...
Funding Programme
Start Date
End Date
Total Funding
€ 221 370
European Countries Involved

Alzheimer disease progression: Molecular studies of Abeta amyloid peptides aggregation and trafficking in neuronal cells

ADPROGRES

Amyloid fibrils are likely causative or contributing agents in diseases such as Alzheimer’s disease, type 2 diabetes, Parkinson’s disease, and transmissible spongiform encephalopathies. AD represents a major health problem and heavy economic burden in industrialized countries. AD is characterized in pathology by the presence of several kinds of...
Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

ANDALUSIAN RESEARCHERS´NIGHT 2012

ANDARES

As part of the Innovation policy of Andalusian Region, Fundación Descubre (www.fundaciondescubre.es) with the University of Almeria, University of Cordoba, University of Granada, University of Huelva, University of Malaga, Pablo de Olavide University, University of Seville, Jaen University and National Research Council (CSIC), the Association of...

Funding Programme
Start Date
End Date
Total Funding
€ 165 217
European Countries Involved

Aqueous Supramolecular Polymers and Peptide Conjugates in Reversible Systems

ASPIRE

Supramolecular polymers are of major interest in the field of self assembly with a promising outlook in areas of viscosity modification, compartmentalized architectures, bio-conjugates and drug-delivery applications. They are dynamic macromolecular materials prepared by simple mixing of relatively small components bearing complementary or self...
Funding Programme
Start Date
End Date
Total Funding
€ 1 700 000
European Countries Involved

BILIVERDIN REDUCTASE-A IN BRAIN INSULIN SIGNALING AND OXIDATIVE STRESS- MEDIATED NEURODEGENERATION

BVRINSULINAD

Alzheimer disease (AD) is the most common form of dementia among the elderly, whose care in Europe demands an amount of financial resources which is rising dramatically making AD a financial problem. Delaying AD onset by 5 years would decrease its prevalence by 50% with an enormous impact on the financial resources involved in AD care. Hence, it is...
Funding Programme
Start Date
End Date
Total Funding
€ 179 740
European Countries Involved

Bioactive compounds from blackcurrant processing waste for brain health

BRAINHEALTHFOOD

Alzheimer's disease (AD) is the most common age-related neurodegerative disorder, and one of the most devastating diagnoses that patients and their families can receive. Currently ~10 % of over 65 year old have AD, and the direct and indirect cost of its care is estimated to be >100 billion $ in the US alone and in the UK ~ €22M, and therefore...
Funding Programme
Start Date
End Date
Total Funding
€ 1 139 467
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).